CRDF vs WATT Comparison

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Energous Corp has developed scalable, over-the-air Wireless Power Network (WPN) technology that integrates semiconductor chipsets, software controls, hardware designs, and antenna systems to enable radio frequency (RF)-based charging for ambient Internet of Things (ambient IoT) devices, transforming supply chain capabilities from limited tracking to overall business intelligence. The WPN technology consists of transmitter systems, receiver integrated circuits, and supporting software designed to deliver power and data to battery-free IoT devices across a range of operating distances and power levels. Its applications include retail sensors, electronic shelf labels (ESLs), asset trackers, air quality monitors, motion detectors, and other monitoring solutions.